Conclusions This meta‐ analysis provides level 1 evidence that vitamin D supplementation may reduce chronic low‐ grade inflammation in patients with type 2 diabetes .
Background Vitamin D has been proposed to have anti‐inflammatory properties ; however , the effect of vitamin D supplementation on inflammation in type 2 diabetes has not been established .
Objective The aim of this systematic review and meta‐ analysis was to examine the effect of vitamin D supplementation on inflammatory markers in patients with type 2 diabetes and to identify relevant gaps in knowledge .
Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease.
AIMS Patients with type 2 diabetes ( T2DM ) and chronic kidney disease ( CKD ) have impaired endothelial function . Vitamin D and its analogs may play a role in regulation of endothelial function and inflammation . We studied effects of paricalcitol compared to placebo on endothelial function and markers of inflammation and oxidative stress in patients with T2DM and CKD . METHODS A double blind , r and omized , placebo-controlled trial was conducted in 60 patients with T2DM and stage 3 or 4 CKD .  Paricalcitol 1 mcg or placebo was administered orally once daily for three months . Brachial artery flow mediated dilatation ( FMD ) , nitroglycerine mediated dilation ( NMD ) , and plasma concentrations of inflammatory cytokines , tumor necrosis factor -α and interleukin-6 , highly-sensitive C-reactive protein ; endothelial surface proteins , intercellular adhesion molecule -1 and monocyte chemo attractant protein-1 , and plasma glucose , insulin , free fatty acids , and urinary isoprostane were measured at baseline and end of three months . RESULTS 27 patients in the paricalcitol group and 28 patients in the control group completed the study , though analysis of FMD at both time points was possible in 23 patients in each group . There was no significant difference in the change in FMD , NMD or the biomarkers examined after paricalcitol or placebo treatment . CONCLUSIONS Treatment with paricalcitol at this dose and duration did not affect brachial artery FMD or biomarkers of inflammation and oxidative stress . The lack of significance may be due to the fact that the study patients had advanced CKD and that effects of paricalcitol are not additive to the effects of glycemic , lipid and anti-hypertensive therapies
Conclusions This meta‐ analysis provides level 1 evidence that vitamin D supplementation may reduce chronic low‐ grade inflammation in patients with type 2 diabetes .
Background Vitamin D has been proposed to have anti‐inflammatory properties ; however , the effect of vitamin D supplementation on inflammation in type 2 diabetes has not been established .
Objective The aim of this systematic review and meta‐ analysis was to examine the effect of vitamin D supplementation on inflammatory markers in patients with type 2 diabetes and to identify relevant gaps in knowledge .